KR950701330A - 칼슘 통로 길항제로서 유용한 n-아일옥시(티오)알킬-아자사이클로알칸(n-aryloxy(thio)alkyl-azacycloadanes useful as calcium channel antagonists) - Google Patents

칼슘 통로 길항제로서 유용한 n-아일옥시(티오)알킬-아자사이클로알칸(n-aryloxy(thio)alkyl-azacycloadanes useful as calcium channel antagonists)

Info

Publication number
KR950701330A
KR950701330A KR1019940703826A KR19940703826A KR950701330A KR 950701330 A KR950701330 A KR 950701330A KR 1019940703826 A KR1019940703826 A KR 1019940703826A KR 19940703826 A KR19940703826 A KR 19940703826A KR 950701330 A KR950701330 A KR 950701330A
Authority
KR
South Korea
Prior art keywords
piperidinoheptane
formula
compound
benzyloxyphenoxy
phenoxy
Prior art date
Application number
KR1019940703826A
Other languages
English (en)
Inventor
헨리 브라운 토마스
그윈 쿠퍼 데이비드
조셉 킹 러날드
Original Assignee
피터 죤 기딩즈
스미스클리인 비참 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929208859A external-priority patent/GB9208859D0/en
Priority claimed from GB929208871A external-priority patent/GB9208871D0/en
Application filed by 피터 죤 기딩즈, 스미스클리인 비참 피엘씨 filed Critical 피터 죤 기딩즈
Publication of KR950701330A publication Critical patent/KR950701330A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

본 발명은 일반식(Ⅰ)의 화합물의 용도에 관한 것이다. 또한 일반식(Ⅰ)의 신규한 화합물, 이를 제조하는 방법 및 이를 함유하는 약제학적 조성물이 기재되어 있다.

Description

칼슘 통로 길항제로서 유용한 N-아릴옥시(티오)알킬-아자사이클로알칸(N-ARYLOXY(THIO)ALKYL-AZACYCLOALDANES USEFUL AS CALCIUM CHANNEL ANTAGONISTS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (18)

  1. 포유 동물의 뇌세포에서 칼슘의 축적과 연관된 질환을 치료하는 약물의 제조에 사용하는 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염의 용도 :
    상기식에서, n은 3 내지 8이고, q는 5 내지 11이며, R1은 C1-6알킬 또는 C1-6알콕시를 나타내며, s는 0, 1또는 2이고, X는 산소 또는 황을 나타내며, Ar은 할로, C1-8알킬, C1-8알콕시, C1-2알킬렌디옥시, 트리플루오로메틸, 트리플루오로메틸옥시 또는 Ph◇(CH2)m-Y-(CH2)p-그룹(여기서, Ph는 임의로 치환된 페닐이고, m 및 p는 독립적으로 0내지 4이며, Y는 결합, 산소, 황 또는 CH=CH이고, 단, m+p는 4보다 크지 않다)중에서 선택된 1내지 3개의 치환체에 의해 임의로 치환된 페닐이거나, 임의 치환된 트리사이클릭 헤테로아릴 그룹 :
    (여기서, Y1은 Y(CH2)x이고, 여기서 X는 0또는 1이며 Y는 O, S 또는 NR이고, 여기서 R은 수소 또는 C1-4알킬이고, Z는 (CH2)r 또는 -CH=CH-이며 r은 0, 1또는 2이다)이거나, 상응하는 트리사이크릭 데하이드로환시스템이다.
  2. 제1항에 있어서, n이 4내지 6인 화합물의 용도.
  3. 제1항 또는 제2항에 있어서, q가 6내지 9인 화합물의 용도.
  4. 제1항 내지 제3항중 어느 한 항에 있어서, s가 0인 화합물의 용도.
  5. 제1항 내지 제4항중 어느 한 항에 있어서, X가 산소인 화합물의 용도.
  6. 제1항 내지 제5항중 어느 한 항에 있어서, Ar이 페녹시, 벤질, 벤질옥시, 또는 할로에 의해 일-치환된 페닐 : 또는 할로에 의해 이치환된 페닐 : 또는 2-벤조푸라닐인 화합물의 용도.
  7. 제1항에 있어서, n은 3 내지 8이고, q는 5 내지 11이며, X는 산소 또는 황을 나타내며, s는 0이고, Ar은 할로, C1-8알킬, 트리플루오로메틸, 트리플루오로메틸옥시 또는 Ph-(CH2)m-Y-(CH2)p-그룹(여기서, Ph는 임의로 치환된 페닐이고, m 및 p는 독립적으로 0내지 4이며, Y는 결합, 산소 또는 황이고, 단, m+p는 4보다 크지 않다)중에서 선택된 1내지 3개의 치환체에 의해 임의로 치환된 페닐이거나, 임의 치환된 트리사이클릭 헤테로아릴 그룹 :
    (여기서, Y1은 Y(CH2)x이고, 여기서 X는 0또는 1이며 Y는 산소, 황 또는 NR이고, 여기서 R은 수소 또는 C1-4알킬이고, Z는 (CH2)r또는 -CH=CH-이며 r은 0, 1또는 2이다)이거나, 상응하는 트리사이크릭 데하이드로환시스템인 화합물 또는 이의 약제학적으로 허용되는 염을 포유동물의 뇌세포에서 칼슘의 축적과 연관된 질환을 치료하는 약물의 제조에 사용하는 용도.
  8. 제1항에 있어서, 화합물이 7-페녹시-1-피페리디노헵탄, 7-(4-플루오로페녹시)-1-피페리디노헵탄, 7-(2,4-디클로로페녹시)-1-피페리디노헵탄, 7-(3,4-디클로로페녹시)-1-피페리디노헵탄, 7-(4-페녹시페녹시)-1-피페리디노헵탄, 7-(3-페녹시페녹시)-1-피페리디노헵탄, 7-(2-디벤조푸라닐옥시)-1-피페리디노헵탄, 7-(4-벤조옥시페녹시)-1-피페리디노헵탄, 7-(4-벤질옥시페녹시)-1-피페리디노헵탄, N-[7-(4-벤질옥시페녹시)헵틸]-헥사메틸렌이민, 6-(3,4-디클로로페녹시)-1-피페리디노헵산, 9-(3,4-디틀로로페녹시)-1-피페리디노노난, 9-(4-벤질옥시페녹시)-1-피페리디노노난, 8-(4-벤질옥시페녹시)-1-피페리디노옥탄, 8-(4-페녹시페녹시)-1-피페리디노옥탄, 6-(4-벤질옥시페녹시)-1-피페리디노헥탄, 7-{4-[2-(4-클로로페닐)에틸]페녹시}-1-피페리디노헵탄, 트랜스-7-[4-(2-페닐에테닐)페녹시]-1-피페리디노헵탄, 7-[4-(2-페닐에틸)페녹시]-1-피페리디노헵탄, 7-(4-벤질페녹시시)-1-피페리디노헵탄, 7-(2-벤질페녹시시)-1-피페리디노헵탄, 7-(4-메톡시페녹시시)-1-피페리디노헵탄, 7-(4-t-부틸페녹시)-1-피페리디노헵탄, 7-(3,4-메틸렌디옥시페녹시)-1-피페리디노헵탄, 7-[4-(3,4-디클로로벤질옥시)페녹시]-1-피페리디노헵탄, 7-[4-(4-메록시벤질옥시)페녹시]-1-피페리디노헵탄, 7-[4-(4-플루오로벤질옥시)페녹시]-1-피페리디노헵탄, N-[7-(4-벤질옥시페녹시)헵틸]-2-메틸피페리딘, N-[7-(4-벤질옥시페녹시)헵틸]-3-메틸피페리딘, N-[7-(4-벤질옥시페녹시)헵틸]-4-메틸피페리딘, N-[7-(4-벤질옥시페녹시)헵틸]-2,6-디메틸피페리딘, N-[7-(4-벤질옥시페녹시)헵틸]-4-메톡시피페리딘, 또는 5-(4-벤질옥시페녹시)-1-피페리디노헵탄, 및 이의 약제학적으로 허용되는 염증에서 선택되는 용도.
  9. 유효량의 제1항 내지 제8항중 어느 한 항에 정의된 바와 같은 일반식(1)의 화합물 또는 이의 약제학적으로 허용되는 염을 이를 필요로하는 환자에게 투여함을 특징으로하여 포유동물의 뇌세포에 칼슘의 축적과 연관된 상태 또는 질환을 치료하는 방법.
  10. 일반식(ⅠA)의 화합물 또는 이의염 :
    상기식에서, n, q, R1, s 및 X는 일반식(Ⅰ)에 정의된 바와같고, Ar1은 일반식(Ⅰ)에 정의된 바와같은 임의로 치환된 트리사이클릭헤테로아릴 그룹이다.
  11. 일반식(ⅠB)의 화합물 또는 이의염 :
    상기식에서, R1, s , n 및 X는 일반식(Ⅰ)에 정의된 바와같고, Ar2는 Ph-(CH2)mY(CH2)p-그룹에 의해 임의 치환된 페닐, 또는 일반식(Ⅰ)에 정의된 바와같은 트리사이클릭헤테로아릴그룹이다.
  12. 제11항에 있어서, Ar2가 일반식(Ⅰ)에 정의된 바와 같은 Ph-(CH2)mY(CH2)p-그룹에 의해 임의로 치환된 페닐인 일반식(ⅠB)의 화합물.
  13. 제11항 또는 제12항에 있어서, s가 0인 일반식(ⅠB)의 화합물.
  14. 7-페녹시-1-피페리디노헵탄, 7-(4-플루오로페녹시)-1-피페리디노헵탄, 7-(2,4-디클로로페녹시)-1-피페리디노헵탄, 7-(4-페녹시페녹시)-1-피페리디노헵탄, 7-(3-페녹시페녹시)-1-피페리디노헵탄, 7-(2-디벤조푸라닐옥시)-1-피페리디노헵탄, 7-(4-벤조옥시페녹시)-1-피페리디노헵탄, 7-(4-벤질옥시페녹시)-1-피페리디노헵탄, N-[7-(4-벤질옥시페녹시)헵틸]-헥사메틸렌이민, 9-(3,4-디틀로로페녹시)-1-피페리디노노난, 9-(4-벤질옥시페녹시)-1-피페리디노노난, 8-(4-벤질옥시페녹시)-1-피페리디노옥탄, 8-(4-페녹시페녹시)-1-피페리디노옥탄, 6-(4-벤질옥시페녹시)-1-피페리디노헥탄, 7-{4-[2-(4-클로로페닐)에틸]페녹시}-1-피페리디노헵탄, 트랜스-7-[4-(2-페닐에테닐)페녹시]-1-피페리디노헵탄, 7-[4-(2-페닐에틸)페녹시]-1-피페리디노헵탄, 7-(4-벤질페녹시시)-1-피페리디노헵탄, 7-(2-벤질페녹시시)-1-피페리디노헵탄, 7-(4-메톡시페녹시시)-1-피페리디노헵탄, 7-(4-t-부틸페녹시)-1-피페리디노헵탄, 7-(3,4-메틸렌디옥시페녹시)-1-피페리디노헵탄, 7-[4-(3,4-디클로로벤질옥시)페녹시]-1-피페리디노헵탄, 7-[4-(4-메록시벤질옥시)페녹시]-1-피페리디노헵탄, 7-[4-(4-플루오로벤질옥시)페녹시]-1-피페리디노헵탄, N-[7-(4-벤질옥시페녹시)헵틸]-2-메틸피페리딘, N-[7-(4-벤질옥시페녹시)헵틸]-3-메틸피페리딘, N-[7-(4-벤질옥시페녹시)헵틸]-4-메틸피페리딘, N-[7-(4-벤질옥시페녹시)헵틸]-2,6-디메틸피페리딘, N-[7-(4-벤질옥시페녹시)헵틸]-4-메톡시피페리딘, 또는 5-(4-벤질옥시페녹시)-1-피페리디노헵탄, 및 이의 약제학적으로 허용되는 염증에서 선택되는 화합물.
  15. 제10항 내지 제14항중 어느한 항의 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염 및 약제학적으로 허용되는 담체 또는 부형제를 함유하는 야 학적 조성물.
  16. 제10항 내지 제14항중 어느한 항의 일반식(Ⅰ)의 화합물 eh는 이의 약제학적으로 허용되는 염 및 약제학적으로 허용되는 담체 또는 부형제를 함유하는, 포유동물의 뇌세포에 칼슘의 축적과 연관된 질환 치료용 약제학적 조성물.
  17. (a) 일반식(Ⅱ)의 화합물을 일반식(Ⅲ)의 화합물과 반응시키거나, (b) 일반식(Ⅳ)의 화합물을 일반식(Ⅴ)의 화합물과 반응시키거나, (c) 일반식 (Ⅵ)또는 (Ⅷ)의 아미드를 환원시키거나, (d) 일반식(Ⅷ)의 알데하이드를 상기 정의된 바와같은 일반식(Ⅴ)의 화합물의 존재하에 환원적 아민화시키거나, (e) Ar3가 PH(CH2)mO-에 의해 치환된 페닐을 나타내는 화합물을 제조하기 위해서, 일반식(IX)의 화합물을 일반식(Ⅹ)의 알킬화제로 알킬화시키거나, (f) n이 5인 화합물을 제조하기 위해서, 일반식(XI)의 피리딘 유도체를 환원시키거나, (g) 일반식(Ⅰ)의 한 화합물을 상이한 일반식(Ⅰ)의 화합물로 상호 전환(예, Y가 CH=CH인 화합물을 Y가 -CH2CH2-화합물로 환원)시킨 후에, 필요한 경우 염을 형성시킴을 포함하여, 제10항 내지 제14항중 어느 한 항에 정의된 바와같은 일반식(Ⅰ)의 화합물의 제조방법 :
    상기식에서, R1, s, q, X 및 n은 일반식(ⅠA)에 정의된 바와같고, Ph는 임의 치환된 페닐이며, n은 0내지 4이고, L1은 친핵체로 치환될 수 있는 그룹이며, Ar3은 q가 일반식(ⅠA)에 정의된 바와같은 경우 Ar1이거나 q가 7일 경우 Ar2이고, L2는 이탈 그룹이며, A-는 짝 음이온이다.
  18. 일반식(Ⅱ), (Ⅳ), (Ⅵ), (Ⅸ) 또는 (XI)의 신규한 중간체.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940703826A 1992-04-24 1993-04-15 칼슘 통로 길항제로서 유용한 n-아일옥시(티오)알킬-아자사이클로알칸(n-aryloxy(thio)alkyl-azacycloadanes useful as calcium channel antagonists) KR950701330A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB929208859A GB9208859D0 (en) 1992-04-24 1992-04-24 Compounds
GB929208871A GB9208871D0 (en) 1992-04-24 1992-04-24 Compounds
GB9208871.5 1992-04-24
GB9208859.0 1992-04-24
PCT/GB1993/000801 WO1993022302A1 (en) 1992-04-24 1993-04-15 N-aryloxy(thio)alkyl-azacycloalkanes useful as calcium channel antagonists

Publications (1)

Publication Number Publication Date
KR950701330A true KR950701330A (ko) 1995-03-23

Family

ID=26300767

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940703826A KR950701330A (ko) 1992-04-24 1993-04-15 칼슘 통로 길항제로서 유용한 n-아일옥시(티오)알킬-아자사이클로알칸(n-aryloxy(thio)alkyl-azacycloadanes useful as calcium channel antagonists)

Country Status (10)

Country Link
EP (1) EP0637303A1 (ko)
JP (1) JPH07506104A (ko)
KR (1) KR950701330A (ko)
CN (1) CN1083055A (ko)
AU (1) AU3959893A (ko)
CA (1) CA2133984A1 (ko)
IL (1) IL105495A0 (ko)
MA (1) MA22880A1 (ko)
SI (1) SI9300217A (ko)
WO (1) WO1993022302A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321811D0 (en) * 1993-10-22 1993-12-15 Smithkline Beecham Plc Pharmaceuticals
EP0755923B1 (en) * 1995-01-23 2005-05-04 Daiichi Suntory Pharma Co., Ltd. Ameliorant or remedy for symptoms caused by Ischemic diseases and Phenylpiperidine compounds useful therefor
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US6251919B1 (en) 1998-02-27 2001-06-26 Warner-Lambert Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US20210309623A1 (en) * 2020-03-11 2021-10-07 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1299247A (en) * 1970-06-22 1972-12-13 Labaz Benzofuran derivatives and process for preparing the same
GB2078217B (en) * 1980-06-14 1984-01-11 Beecham Group Ltd Phenolic ethers their preparation and use
JPS58113140A (ja) * 1981-12-14 1983-07-05 シンテツクス（ユ−・エス・エイ）インコ−ポレイテツド ナフトキシアルキル化合物、その製造法およびそれからなる抗炎症剤
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
DE3706585A1 (de) * 1987-02-25 1988-09-08 Schering Ag Aryl- und aryloxy-substituierte tert.-alkylenamine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
CA2020888A1 (en) * 1989-07-27 1991-01-28 Philippe Guerry Substituted aminoalkoxybenzene derivatives
TW199153B (ko) * 1990-08-07 1993-02-01 Dtsuka Seiyaku Kk

Also Published As

Publication number Publication date
EP0637303A1 (en) 1995-02-08
WO1993022302A1 (en) 1993-11-11
JPH07506104A (ja) 1995-07-06
CN1083055A (zh) 1994-03-02
MA22880A1 (fr) 1993-12-31
IL105495A0 (en) 1993-08-18
AU3959893A (en) 1993-11-29
CA2133984A1 (en) 1993-11-11
SI9300217A (sl) 1993-12-31

Similar Documents

Publication Publication Date Title
PT95389A (pt) Processo para a preparacao de novos derivados pirazolicos com accao anti-inflamatoria
LU90011I2 (fr) Remifentanil facultativement sous la forme d'un sel d'addition d'acide pharmaceutiquement acceptable y compris le chlorhydrate de remifentanil
AU4780699A (en) Farnesyl protein transferase inhibitors for treating arthropathies
ES2173875T3 (es) Derivados de pirazol con actividad antiinflamatoria, analgesica y antitrombotica.
MX9204746A (es) Nuevos derivados de tiazolilbenzofuranos, procedimientos para la preparacion de los mismos y las composiciones farmaceuticas que los contienen.
UA66852C2 (uk) Похідні та аналоги 3-арилпропіонової кислоти, спосіб їх отримання, фармацевтична композиція (варіанти) та спосіб профілактики та/або лікування асоційованих з резистентністю до інсуліну клінічних станів
RU96108927A (ru) Терапевтические средства
KR910015562A (ko) 뇌부전 질환치료용 약제, 신규 2-(1-피페라지닐)-4-페닐시클로알카노 피리미딘 유도체, 및 그의 제법
HRP20050517A2 (en) N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobial agents
JP2572558B2 (ja) ポドフイロトキシンよりなるマラリヤの治療剤
KR950701330A (ko) 칼슘 통로 길항제로서 유용한 n-아일옥시(티오)알킬-아자사이클로알칸(n-aryloxy(thio)alkyl-azacycloadanes useful as calcium channel antagonists)
IL110060A0 (en) 5-Amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
KR930001832B1 (ko) 천식 또는 특정 피부 질환의 치료를 위한 피리미돈 유도체 및 동족체
DE3686979D1 (de) Cephemverbindungen und verfahren zu ihrer herstellung.
MA27492A1 (fr) Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
EP0371388A3 (en) Acridine derivatives
RU95109440A (ru) Производные 4-хинолинила, обладающие антигеликобактериальной активностью, способ их получения, фармацевтическая композиция, их содержащая, и способ ее получения
SE9900190D0 (sv) New compounds
IE882703L (en) N-£substituted alkylidene|-1,2,3,4-tetrahydro-9-acridinamines, a process for their preparation and their use as medicaments
FI891155A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 4,5,6,7-tetrahydroisotiatsolo/4,5-c/pyridiini-johdannaisten ja niiden isomeerien ja happoadditiosuolojen valmistamiseksi
CA2140781A1 (en) Pharmocologically active .alpha.-¬tertiary-aminomethyl|- benzenemethanol derivatives
PT99674A (pt) Processo para a preparacao de 5-amino-5,6,7,8-tetra-hidroquinolinas e de composicoes farmaceuticas que as contem
JPWO2002042284A1 (ja) ジベンゾスベラニルピペラジン誘導体および該誘導体を含む薬剤耐性克服剤
KR910002855A (ko) 5 6-디하이드로[1H-인돌로[3,2,-c]퀴놀린-6,4-피페리딘] 및 관련화합물, 이의 제조방법 및 약제로서의 용도
DK162286C (da) Penemderivat, farmaceutisk praeparat indeholdende dette, anvendelse af derivatet samt fremgangsmaader til fremstilling deraf

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid